This lack of consistency in the literature between cancer model, ATR inhibitor used and the experimental method of ATM depletion employed led us to undertake an assessment of how ATM status affects ATRi sensitivity in PDAC cells, specifically using AZD6738 with and without gemcitabine, in alignment with the ATRiUM trial. The gene discussed is ATR; the disease is cancer.